Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells. Unusually high sensitivity of ERCC2 and ERCC3 DNA helicase-deficient mutants in comparison to other chemotherapeutic agents.
Illudins, novel natural products with a structure unrelated to any other known chemical, display potent in vitro and in vivo anti-cancer activity against even multi-drug resistant tumors, and are metabolically activated to an unstable intermediate that binds to DNA. The DNA damage produced by illudins, however, appears to differ from that of other known DNA damaging toxins. The sensitivity pattern of the various UV-sensitive cell lines differs from previously studied DNA cross-linking agents. Normally, the ERCC1- (excision repair cross complementing) and ERCC4-deficient cell lines are most sensitive to DNA cross-linking agents, with ERCC2-, ERCC3- and ERCC5-deficient cell lines having minimal sensitivity. With illudins the pattern is reversed, with ERCC2 and ERCC3 being the most sensitive. The sensitivity to illudins in complementation groups 1 through 3 is due to a deficiency of the ERCC1-3 gene products, as cellular drug accumulation studies revealed no differences in transport capacity or total drug accumulation. Also, a transgenic cell line in which ERCC2 activity was expressed through an expression vector regained its relative resistance to the illudins. The EM9 cell line, which displays sensitivity to monoadduct producing chemicals, was not sensitive. Thus, excision repair is involved in repair of illudin-induced damage and, unlike other anti-cancer agents, the involvement of ERCC2 and ERCC3 helicases is critical for repair to occur. The requirement for ERCC2 and ERCC3, combined with the finding that ERCC1 but not ERCC2 is upregulated in drug-resistant tumors, may explain the efficacy of illudins against drug-resistant tumors. The inhibition of DNA synthesis in cells within minutes after exposure to illudins at nanomolar concentrations may be related to the finding that the ERCC3 gene product is actually the p89 helicase component of the BTF2 (TFII) basic transcription factor and the high sensitivity of ERCC3-deficient cells to illudins.
Kelner
M J
MJ
Department of Pathology, University of California, San Diego 92103-8320.
McMorris
T C
TC
Estes
L
L
Rutherford
M
M
Montoya
M
M
Goldstein
J
J
Samson
K
K
Starr
R
R
Taetle
R
R
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D002330:Carmustine / Q000494:pharmacology; D002460:Cell Line / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology; D006224:Cricetinae; D003412:Cricetulus; D004247:DNA / Q000302:isolation & purification; D004249:DNA Damage; D004265:DNA Helicases / Q000172:deficiency* / Q000235:genetics; D004268:DNA-Binding Proteins / Q000235:genetics; D008937:Mitomycins / Q000494:pharmacology; D009154:Mutation; D000081223:Polycyclic Sesquiterpenes; D012717:Sesquiterpenes / Q000494:pharmacology
D000903:Antibiotics, Antineoplastic; D004268:DNA-Binding Proteins; D008937:Mitomycins; D000081223:Polycyclic Sesquiterpenes; D012717:Sesquiterpenes; C095888:xeroderma pigmentosum group F protein; D004247:DNA; D004265:DNA Helicases; C008105:illudin S; D002945:Cisplatin; D002330:Carmustine